Study

You are here

Protocol GS-US-380-1961:

Protocol GS-US-380-1961: The study evaluates the efficacy of switching to an FDC of GS-9883/ F/TAF in virologically suppressed HIV-1 infected women as determined by the proportion of subjects with virologic failure at Week 48.


A5264: A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067

Sponsor:

  • AIDS Clinical Trials Group

Collaborator:

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Information provided by (Responsible Party):
  • AIDS Clinical Trials Group

A5288: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULT-OCTAVE)

The aim is to test a strategy of using resistance testing to choose the optimal ART regimen in those failing 2nd line Therapy. 

Sponsor:

  • AIDS Clinical Trials Group

Collaborator:

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Information provided by (Responsible Party):
  • AIDS Clinical Trials Group

Strategic Timing of AntiRetroviral Treatment (START)

The main objective is to assess the development of serious illness or AIDS when ART is initiated at fairly highCD4+ Compared to waiting until the CD4+ count is at the level where there is good evidence for starting therapy.


Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity

Gilead Protocol GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS9883 /Emtricitabine Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children